Concentra Biosciences to Acquire IGM Biosciences in a $82.85 Million Deal

IGM Biosciences, Inc. (IGMS) entered a merger agreement on July 1, 2025, to be acquired by Concentra Biosciences, LLC for $82.85 million.

Deal Structure:

Under the terms of the agreement, Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock, plus one non-tradeable contingent value right (CVR), which represents the right to receive:

1. 100% of the closing net cash of IGM Biosciences in excess of $82 million; and
2. 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences’ product candidates and intellectual property that occurs within one year following closing.

The cash consideration of $1.247 per share represents a premium of 11.34% from the stock’s last close.

Company Profile:

IGM Biosciences is a biotechnology company developing engineered IgM antibodies to treat cancer, infectious diseases, and autoimmune disorders. Its pipeline includes candidates targeting B-cell lymphomas, solid tumors, multiple myeloma, and leukemia.

Deal Details and Timeline:

Concentra will commence a tender offer by July 16, 2025, and the merger is expected to close in August 2025.

Wilson Sonsini Goodrich & Rosati is serving as legal counsel to IGM Biosciences, while Gibson, Dunn & Crutcher is serving as legal counsel to Concentra.

Deal Metrics:

For a more comprehensive understanding of this merger and acquisition deal, visit the Deal Metrics page here:

Deal Metrics for the acquisition of IGM Biosciences, Inc. (IGMS) by Concentra Biosciences, LLC

The Deal Metrics page for each merger or acquisition includes:

– A spread history chart of the merger from announcement to finalization or termination.
– A timeline of key events – HSR period expiration, regulatory approvals, shareholder votes, etc.
– Relevant news and SEC filings.
– A historical record of deal updates.
– And much more.

Disclaimer: This article is meant for informational purposes only. Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article